ArticleCell journal
Thymoquinone Could Increase The Efficacy of Tamoxifen Induced Apoptosis in Human Breast Cancer Cells: An In Vitro Study.
Article in Cell journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Harmine reduces ROS-mediated hepatotoxicity in a cisplatin mouse model.Research in pharmaceutical sciences · 2026Article
- Targeting Cancer Through Thymoquinone: From Molecular Mechanisms to Clinical Prospects.International journal of molecular sciences · 2025Review
- In Vitro Evaluation of Olive Leaf (Pharmaceuticals (Basel, Switzerland) · 2025Article
- Anticancer potential of Thymoquinone from Nigella sativa L.: An in-silico and cytotoxicity study.PloS one · 2025Article
- Harnessing the nutriceutics in early-stage breast cancer: mechanisms, combinational therapy, and drug delivery.Journal of nanobiotechnology · 2024Review
- Anticancer effect of terpenes: focus on malignant melanoma.Pharmacological reports : PR · 2023Review
- An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management.Journal of personalized medicine · 2023Review
- Targeting microRNAs with thymoquinone: a new approach for cancer therapy.Cellular & molecular biology letters · 2021Review
- Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells.World journal of clinical oncology · 2021Review
- Tamoxifen and oxidative stress: an overlooked connection.Discover oncology · 2021Review
- Thymoquinone anticancer activity is enhanced when combined with royal jelly in human breast cancer.World journal of clinical oncology · 2021Article
- Review
- Review
- Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets.Journal of cancer prevention · 2020Review
- Thymoquinone-chemotherapeutic combinations: new regimen to combat cancer and cancer stem cells.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
- Medicinal Herbs Used in Traditional Management of Breast Cancer: Mechanisms of Action.Medicines (Basel, Switzerland) · 2020Review
- Synergistic Effects of Lauryl Gallate and Tamoxifen on Human Breast Cancer Cell.Iranian journal of public health · 2020Article
- Thymoquinone Enhances Paclitaxel Anti-Breast Cancer Activity via Inhibiting Tumor-Associated Stem Cells Despite Apparent Mathematical Antagonism.Molecules (Basel, Switzerland) · 2020Article
- Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives.RSC advances · 2018Review
- Thymoquinone, as an anticancer molecule: from basic research to clinical investigation.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThymoquinone (TQ), as the main component of Nigella Sativa plant, shows anticancer properties. This study was aimed to evaluate the combined effect of TQ and Tamoxifen (TAM) on viability and apoptosis of human breast cancer cell lines. MATERIALS AND
methodsIn this experimental study, estrogen positive MCF-7 and estrogen negative MDA-MB-231 human breast cancer cell lines were induced by TAM (2 µM) or different doses of TQ (50, 75, 100, 150 µM), individually or in combination. Cell viability and apoptosis were investigated by MTT assay and TdT-mediated deoxy-uracil nick end labeling (TUNEL) assay; Acridine orange (AO)/Ethidium bromide (EB) staining respectively. Data were analyzed by one way ANOVA and P<0.05 was considered significant.
resultsIn 24 hours treatment, TAM and all doses of TQ, solely or in combination, significantly reduced cell viability of both cell lines, except in MCF-7 cells treated with 50 µM TQ, and MDA-MB-231 cells treated with 50 or 75 µM TQ (P<0.01). After 48 hours treatment, cell viability of both cell lines was reduced in all treated groups (P<0.05). Remarkable apoptotic index was observed in combination treatment of MCF-7 or MDA-MB-231 cell lines with TAM and TQ (P<0.001).
conclusionThe synergistic effect of TQ and TAM on human breast cancer cell lines showed cell viability reduction as well as apoptosis induction, independent to estrogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.